Latest Comparison,Sequence

The intricate world of molecular biology and peptide therapeutics has seen significant advancements, with the FOXO4-DRI peptide sequence emerging as a focal point in the study of cellular senescence and aging. This peptide, a synthetic derivative of the FOXO4 protein, has garnered considerable attention for its potential to selectively eliminate senescent cells, a process known as senolysis. Understanding the precise sequence of FOXO4-DRI is crucial for comprehending its mechanism of action and its therapeutic implications.

At its core, FOXO4-DRI stands for the FOXO4 D-Retro-Inverso peptide. This modification involves reversing the amino acid sequence and utilizing D-amino acids instead of the more common L-amino acids. This structural alteration enhances the peptide's stability and resistance to degradation within the body. Several variations of the FOXO4-DRI peptide sequence have been reported in scientific literature and commercial offerings. One commonly cited sequence is H-ltlrkepaseiaqsileaysqngwanrrsggkrppprrrqrrkkrg-OH. Another representation, particularly when referring to the D-amino acid form, is Sequence: H-D-Leu-D-Thr-D-Leu-D-Arg-D. The FOXO4 D-Retro-Inverso peptide acetate, for instance, is associated with the sequence D-(Leu-Thr-Leu-Arg-Lys-Glu-Pro-Ala-Ser-Glu-Ile-Ala-Gln-Ser-Ile-Leu-Glu-Ala-Tyr-Ser-G. A shortened version, often used in research, is LTLRKEPASEIAQSILEAYSQNGWANRRSGGKRP.

The significance of the FOXO4-DRI peptide lies in its ability to disrupt the interaction between the FOXO4 protein and p53. FOXO4 is a transcription factor involved in various cellular processes, including cell cycle arrest and apoptosis. p53, a critical tumor suppressor protein, plays a vital role in preventing genomic mutations and initiating cell death in response to DNA damage. In senescent cells, the FOXO4-p53 complex is often stabilized, contributing to their survival and the release of pro-inflammatory factors that promote aging and age-related diseases.

FOXO4-DRI acts as a peptide antagonist, effectively blocking this detrimental FOXO4 and p53 interaction. By interfering with this binding, the FOXO4-DRI peptide prompts senescent cells to undergo apoptosis, thereby clearing them from tissues. This selective elimination of senescent cells is a key aspect of senolytic peptide FOXO4-DRI therapy. Research indicates that FOXO4-DRI can significantly improve vascular function and delay vascular aging, highlighting its potential in combating age-related decline.

The molecular weight of FOXO4-DRI is approximately 5358.05 g/mol, with a molecular formula of C228H388N86O64 for the FOXO4 D-Retro-Inverso(DRI) peptide. These precise parameters are critical for researchers and manufacturers to ensure the quality and efficacy of the peptide. The FOXO4-DRI peptide is described as a cell-permeable peptide antagonist, allowing it to readily enter cells and exert its effects.

The term "DRI" itself signifies the D-retro inverso modification, a crucial feature that confers stability to the peptide. This modification is central to the design of FOXO4-DRI as a therapeutic agent. The FOXO4 DRI Peptide is essentially a modified version of the FOXO4 peptide, designed to enhance its biological activity.

While the research on FOXO4-DRI is promising, it is important to note that it is primarily used for laboratory research and is not approved for human use. Studies are ongoing to explore its potential benefits in various age-related conditions. The learn about FOXO4-DRI peptide benefits aspect is a testament to the growing interest in its therapeutic applications. However, potential side effects and optimal dosages are subjects of ongoing investigation, and information regarding FOXO4-DRI dosage chart and FOXO4-DRI reviews should be approached with caution, emphasizing its current research-oriented status.

In summary, the FOXO4-DRI peptide sequence represents a sophisticated approach to targeting cellular senescence. By understanding the specific amino acid arrangements and the D-retro inverso modification, scientists are unlocking new avenues for research into aging and age-related diseases. The ability of FOXO4-DRI to selectively induce apoptosis in senescent cells, by disrupting the FOXO4-p53 interaction, positions it as a significant player in the evolving landscape of senolytic therapies. The ongoing exploration of FOXO4-DRI and its potential applications underscores the power of peptide-based interventions in modern medicine.